GlassScriptPhysician profile
Laura D Buch
NPI 1346801164
$72,648.75
in general payments reported to CMS, 2019-2025
14 companies · $27K in 2025
The $27K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,504 · 2022: $5,095 · 2023: $9,480 · 2024: $27K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Travel and Lodging: $7,648 · Honoraria: $3,440 · Food and Beverage: $3,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,171.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,657.00 |
| Travel and Lodging | $7,647.86 |
| Honoraria | $3,440.00 |
| Food and Beverage | $3,134.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $54,416.32 | 2021-2025 | |
| Chiesi USA, INC. | $9,342.17 | 2022-2025 | Lamzede, Elfabrio |
| Amicus Therapeutics, INC. | $3,591.98 | 2021-2025 | Pombiliti, Opfolda, Galafold |
| Horizon Therapeutics Plc | $2,394.40 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,305.59 | 2021-2025 | Elaprase, Vpriv |
| Zevra Therapeutics INC | $1,043.05 | 2024-2025 | Olpruva |
| Ptc Therapeutics, INC. | $223.90 | 2025 | Sephience |
| Biomarin Pharmaceutical INC. | $132.29 | 2022-2024 | Voxzogo 1.2mg |
| Ultragenyx Pharmaceutical INC. | $72.67 | 2022-2024 | Dojolvi |
| Cycle Pharmaceuticals INC | $53.48 | 2024-2025 | Javygtor |
| Alexion Pharmaceuticals, INC. | $21.23 | 2025 | Koselugo |
| Eton Pharmaceuticals, INC. | $19.51 | 2023 | Carglumic Acid |
| Ucb, INC. | $16.97 | 2025 | |
| Sanofi-Aventis U.S. LLC | $15.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Buch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.